Novartis AG
[NVS]
NYSE
MVPro™ Score: 57/100
Last Earnings: 28 Oct 2025
[NVS]
NYSE
MVPro™ Score: 57/100
Last Earnings: 28 Oct 2025
Powered by AI
| Capitalization (mln USD) | 226,635 |
| Revenue (mln USD) | 14,836 |
| EBITDA (mln USD) | 4,864 |
| Net Income (mln USD) | 4,041 |
| Net Margin | 27.24% |
| EPS Ratio (TTM, USD) | 6.97 |
| P/E Ratio (TTM) | 16.6 |
| P/S Ratio (TTM) | 4.3 |
| D/E Ratio | 1.48 |
| EV/EBITDA (TTM) | 14.97 |
| CAPEX (Q/Q) | -62.65% |
| Dividend Yield | 3.22% |
Revenue, EBITDA & Net Income
Company Overview
Novartis AG is a global healthcare company headquartered in Basel, Switzerland, with a history dating back to the mid-1990s after the merger of Ciba-Geigy and Sandoz. The firm has grown into one of the world’s most significant pharmaceutical players, building on a legacy of innovation and research excellence. Today, Novartis is recognised not only for its scale but also for its focus on advancing modern medicine and improving patient worldwide.
The company’s operations focus on research, development, and commercialisation of innovative medicines, with emphasis on oncology, immunology, and cardiovascular therapies. Its leading products include treatments for cancer, eye diseases, and neurological disorders, placing it at the forefront of addressing major medical needs. Novartis also invests in gene and cell therapies, strengthening its position as a pioneer in next-generation solutions.
Vas Narasimhan currently serves as the Chief Executive Officer, guiding the group with a mission to reimagine medicine and improve and extend people’s lives. Novartis maintains a presence in over 150 countries, with particularly strong market positions in Europe, North America, and emerging economies. The company also demonstrates a firm commitment to environmental, social, and governance (ESG) principles, embedding sustainability, ethical conduct, and access to medicines as core elements of its long-term strategy.
🟡 P/E (Price to Earnings, TTM)
Price-to-earnings (P/E) ratio for the most recent quarter is 17.4, compared to 17.2 in the previous quarter, with a longer-term trend value of 16.1. This increase in the P/E ratio suggests a higher valuation of the company by investors, potentially driven by strong growth expectations, earnings stability, or increased market confidence.
P/E Ratio
Source: MarketVectors.Pro, Novartis Financial Reports (TTM)
P/E Ratio
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Full Premium Plan.
Download now with your Full Premium Plan.
🟢 EPS (Earnings Per Share, TTM)
Novartis's earnings per share (EPS) for the most recent quarter is 6.97 USD (+7.2%), compared to 6.50 USD in the previous quarter, with a longer-term trend value of 7.29 USD. This quarterly increase in EPS suggests improved profitability and operational efficiency.
EPS
Source: MarketVectors.Pro, Novartis Financial Reports (TTM, USD)
EPS
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Full Premium Plan.
Download now with your Full Premium Plan.
Unlock the Power of Financial Intelligence
Built for everyday investors, professionals and everyone in between.
Start for Free – No Credit Card NeededBest for informed investors seeking deeper insights
Built for professionals and power users who want it all
Register for FREE Now
Disclaimer
This report is provided for informational purposes only and does not constitute financial, investment, legal, tax, or professional advice. The information, analyses, forecasts, and opinions contained herein are based on sources believed to be reliable as of the publication date. However, MarketVectors.Pro, its affiliates, officers, directors, employees, and agents make no warranties or representations, express or implied, regarding the accuracy, completeness, reliability, or suitability of this information for any particular purpose. The data, assumptions, and projections provided are subject to change without notice.
No Investment or Legal Advice
This report does not constitute an offer, recommendation, or solicitation to buy, sell, or hold any financial instrument, security, commodity, or investment. Any investment decisions made by the recipient are made entirely at their own discretion and risk. MarketVectors.Pro and its affiliates expressly disclaim any and all liability for investment losses, financial damages, or any other consequences arising from reliance on this report, whether such losses result from errors, omissions, misinterpretations, or unforeseen market conditions.
The recipient acknowledges and agrees that MarketVectors.Pro shall not be held liable under any legal theory, including but not limited to negligence, breach of fiduciary duty, or misrepresentation, for any direct, indirect, incidental, consequential, or punitive losses incurred. Furthermore, past performance is not indicative of future results, and no assurance or warranty is given regarding the accuracy, completeness, or reliability of the information contained herein. The recipient is strongly encouraged to seek independent professional advice before making any financial decisions.
This report may contain inaccuracies, errors, or omissions. MarketVectors.Pro and its affiliates expressly disclaim any responsibility for such inaccuracies and make no warranties, express or implied, regarding the correctness or completeness of the information provided. The recipient agrees not to hold MarketVectors.Pro liable for any such inaccuracies or their consequences.
Forward-Looking Statements and Risk Disclosures
This report may contain forward-looking statements based on assumptions, estimates, and expectations that are inherently subject to known and unknown risks and uncertainties. Actual results may differ materially from those projected due to factors beyond the control of MarketVectors.Pro, including but not limited to market fluctuations, geopolitical events, regulatory changes, and macroeconomic conditions. No assurances or guarantees can be made that any projections, expected returns, or forecasts will be realized.
Past performance is not indicative of future results. The recipient acknowledges that all forward-looking statements are inherently uncertain and that actual results may differ significantly from projections. MarketVectors.Pro does not guarantee any level of performance or return on investment.
Jurisdictional and Regulatory Considerations
This document is intended for recipients in jurisdictions where its distribution and access are legally permitted. It may not comply with regulatory standards in all jurisdictions and should not be used or relied upon in any jurisdiction where such distribution would violate local laws or regulations. Recipients are responsible for ensuring compliance with applicable local laws before engaging in any financial activities based on this report.
Confidentiality and Restriction on Distribution
This report is confidential and solely intended for the designated recipient. It may not be copied, reproduced, distributed, or shared without the prior written consent of MarketVectors.Pro. Unauthorized use or distribution of this document may be subject to legal action under applicable intellectual property and confidentiality laws.
Limitation of Liability
To the fullest extent permitted by law, MarketVectors.Pro, its affiliates, officers, directors, employees, and representatives expressly disclaim any and all liability for any damages or losses, whether direct, indirect, incidental, consequential, punitive, or otherwise, arising from the use or reliance on this report.
By accessing or using this report, the recipient acknowledges and agrees to the above terms and waives any claims against MarketVectors.Pro and its affiliates related to the content, analysis, or recommendations provided.
